Keros Therapeutics Inc

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. Its lead candidates include rinvatercept, a ligand trap that inhibits the biological effects of myostatin and activin A, in Phase 1 trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis, and elritercept, which targets TGF-β signaling pathways to address diseases arising from ineffective hematopoiesis, in Phase 3 trials for Myelodysplastic Syndromes and Phase 2 trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.